PCVX

Vaxcyte, Inc. PCVX

PCVX
Vaxcyte, Inc. CRSP
CRISPR Therapeutics AG ARWR
Arrowhead Pharmaceuticals, Inc. PTCT
PTC Therapeutics, Inc. KRYS
Krystal Biotech, Inc. TGTX
TG Therapeutics, Inc. MTSR
Metsera, Inc. ALKS
Alkermes plc CRNX
Crinetics Pharmaceuticals, Inc. ACLX
Arcellx, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode PCVX CRSP ARWR PTCT KRYS TGTX MTSR ALKS CRNX ACLX
6M 29.16 % 35.33 % 335.99 % 47.00 % 82.83 % -11.82 % 139.96 % -4.21 % 58.11 % 6.63 %
YTD -46.77 % 35.82 % 248.35 % 66.19 % 55.42 % 1.16 % 166.04 % -1.98 % -4.31 % -13.22 %
1Y -50.45 % 27.19 % 205.99 % 56.86 % 45.12 % -8.66 % 166.04 % -8.12 % -9.70 % -18.08 %
3Y -3.19 % 21.25 % 115.45 % 94.42 % 204.66 % 296.72 % 166.04 % 10.42 % 192.76 % 114.57 %
5Y 36.35 % -61.62 % -11.83 % 17.80 % 308.53 % -41.06 % 166.04 % 31.07 % 254.38 % 306.79 %
10Y 69.56 % 299.36 % 1 097.73 % 124.00 % 2 186.09 % 177.81 % 166.04 % -64.17 % 101.26 % 306.79 %
From the beginning 69.56 % 299.36 % -97.66 % 362.40 % 2 186.09 % -86.04 % 166.04 % 412.36 % 101.26 % 306.79 %

Dividend